Boughton Soleil, the Chief Legal Officer at Hims & Hers Health, Inc., recently sold 3,461 shares of Class A common stock. The transaction took place on October 14, 2026, and was reported in a filing made on October 15, 2026. This sale is part of a Rule 10b5-1 trading plan that Soleil adopted earlier this year.
This sale is significant as it reflects Soleil's ongoing trading activity within the company, which is a notable player in the healthcare services sector. The transaction was executed at a price of $29.06 per share, totaling approximately $100,000. Following this sale, Soleil retains ownership of 297,348 shares of Hims & Hers.
Background
Hims & Hers Health, Inc. operates in the healthcare services industry, specifically focusing on telehealth and wellness products. The company is publicly traded under the ticker symbol HIMS and is listed on the New York Stock Exchange. Hims & Hers aims to provide accessible healthcare solutions and has been recognized for its innovative approach to telemedicine.
What the Filing Says
The SEC filing, accession number 0001773751-26-000227, indicates that the shares sold were part of a pre-established trading plan. The filing notes, “The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026 by the Reporting Person.” This suggests that the transaction was planned in advance, which is a common practice to avoid any appearance of insider trading.
Impact
This sale may affect various stakeholders, including investors and competitors in the healthcare services industry. Investors often scrutinize insider transactions as indicators of a company's health and future prospects. The healthcare services sector, characterized by companies offering medical services, is likely to observe how Hims & Hers navigates its growth strategies amidst ongoing market changes.
What's Next
The filing does not say what happens next.